VRDN
insider transactionsViridian Therapeutics, Inc.\DE — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-2.3K
0 buy · 2.3K sell
Net value · 365d
-$70.8K
$0 in · $70.8K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
1
0 buy · 2.3K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Exercise·M
Chief Legal Officer
$0
5.2K sh
Own +50%
-
Other·F
Chief Legal Officer
$50.5K
1.7K sh · $29.32
Own -33%
-
Exercise·M
Chief Legal Officer
—
5.2K sh
Own New
-
Exercise·M
President and CEO
$0
18.4K sh
Own +50%
-
Other·F
President and CEO
$223.6K
7.6K sh · $29.32
Own -19%
-
Exercise·M
President and CEO
—
18.4K sh
Own +82%
-
Exercise·M
Seth Harmon KEY
Chief Financial Officer
$0
6.3K sh
Own +50%
-
Other·F
Seth Harmon KEY
Chief Financial Officer
$61.3K
2.1K sh · $29.32
Own -21%
-
Exercise·M
Seth Harmon KEY
Chief Financial Officer
—
6.3K sh
Own +173%
-
Exercise·M
Chief Operating Officer
$0
9.4K sh
Own +50%
-
Other·F
Chief Operating Officer
$92.0K
3.1K sh · $29.32
Own -19%
-
Exercise·M
Chief Operating Officer
—
9.4K sh
Own +134%
-
Other·F
Chief Legal Officer
$50.6K
1.7K sh · $30.19
Own -32%
-
Other·F
President and CEO
$223.6K
7.4K sh · $30.19
Own -18%
-
Other·F
Seth Harmon KEY
Chief Financial Officer
$61.3K
2.0K sh · $30.19
Own -21%
-
Other·F
Chief Operating Officer
$92.0K
3.0K sh · $30.19
Own -19%
-
Grant·A
Chief Medical Officer
$0
19.1K sh
Own New
-
Grant·A
Chief Medical Officer
$0
95.8K sh
Own New
-
Grant·A
Chief Legal Officer
$0
23.9K sh
Own New
-
Grant·A
Chief Legal Officer
$0
119.3K sh
Own New
-
Grant·A
President and CEO
$0
111.9K sh
Own New
-
Grant·A
President and CEO
$0
559.6K sh
Own New
-
Grant·A
Seth Harmon KEY
Chief Financial Officer
$0
20.6K sh
Own New
-
Grant·A
Seth Harmon KEY
Chief Financial Officer
$0
102.8K sh
Own New
-
Grant·A
Chief Operating Officer
$0
35.3K sh
Own New
-
Grant·A
Chief Operating Officer
$0
176.6K sh
Own New
-
Sell·S
Chief Legal Officer
$70.8K
2.3K sh · $31.16
Own -100%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 3, 2026 | Jennifer Tousignant | Exercise M | 5.2K | $0 |
| Mar 3, 2026 | Jennifer Tousignant | Other F | 1.7K | $50.5K |
| Mar 3, 2026 | Jennifer Tousignant | Exercise M | 5.2K | — |
| Mar 3, 2026 | Stephen F. Mahoney KEY | Exercise M | 18.4K | $0 |
| Mar 3, 2026 | Stephen F. Mahoney KEY | Other F | 7.6K | $223.6K |
| Mar 3, 2026 | Stephen F. Mahoney KEY | Exercise M | 18.4K | — |
| Mar 3, 2026 | Seth Harmon KEY | Exercise M | 6.3K | $0 |
| Mar 3, 2026 | Seth Harmon KEY | Other F | 2.1K | $61.3K |
| Mar 3, 2026 | Seth Harmon KEY | Exercise M | 6.3K | — |
| Mar 3, 2026 | Thomas W. Beetham | Exercise M | 9.4K | $0 |
| Mar 3, 2026 | Thomas W. Beetham | Other F | 3.1K | $92.0K |
| Mar 3, 2026 | Thomas W. Beetham | Exercise M | 9.4K | — |
| Mar 3, 2026 | Jennifer Tousignant | Other F | 1.7K | $50.6K |
| Mar 3, 2026 | Stephen F. Mahoney KEY | Other F | 7.4K | $223.6K |
| Mar 3, 2026 | Seth Harmon KEY | Other F | 2.0K | $61.3K |
| Mar 3, 2026 | Thomas W. Beetham | Other F | 3.0K | $92.0K |
| Mar 2, 2026 | Radhika Tripuraneni | Grant A | 19.1K | $0 |
| Mar 2, 2026 | Radhika Tripuraneni | Grant A | 95.8K | $0 |
| Mar 2, 2026 | Jennifer Tousignant | Grant A | 23.9K | $0 |
| Mar 2, 2026 | Jennifer Tousignant | Grant A | 119.3K | $0 |
| Mar 2, 2026 | Stephen F. Mahoney KEY | Grant A | 111.9K | $0 |
| Mar 2, 2026 | Stephen F. Mahoney KEY | Grant A | 559.6K | $0 |
| Mar 2, 2026 | Seth Harmon KEY | Grant A | 20.6K | $0 |
| Mar 2, 2026 | Seth Harmon KEY | Grant A | 102.8K | $0 |
| Mar 2, 2026 | Thomas W. Beetham | Grant A | 35.3K | $0 |
| Mar 2, 2026 | Thomas W. Beetham | Grant A | 176.6K | $0 |
| Dec 31, 2025 | Jennifer Tousignant | Sell S | 2.3K | $70.8K |
About VRDN insider trading
This page tracks insider transactions for Viridian Therapeutics, Inc.\DE (VRDN) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.